Delivery Order SPE2DB20D3103-SPE2DB25FP2E3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $19,341.02 on July 22, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,104.98 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Mekinist 0.5 mg tablets (30-count units). This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 25, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical supply needs,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Mekinist 0.5 mg tablets (30-count units) under a firm fixed-price contract valued at $2,850.83. The award, issued on May 1, 2025, with completion targeted for May 22, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $8.55K to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Mekinist 0.5 mg tablets (30-count units). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,670.51 on September 9, 2025, for the supply of Mekinist 2 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is set to be completed by September 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $19.3K delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Mekinist 2 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with a completion date of May 12, 2025, and performance based in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Mekinist 2 mg tablets (30-count units) valued at $9,670.51 with a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 25, 2025, and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,104.98 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Mekinist 0.5 mg tablets (30-count units), with an ultimate completion date of October 16, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency (DLA) awarded a $30,714.72 firm fixed price delivery order to AmerisourceBergen Drug Corp for 30 units of Mekinist 0.5 mg tablets, with an ultimate completion date of July 31, 2025. This non-set-aside, competitively awarded contract was issued on July 10, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy used in the treatment of melanoma and other malignancies, representing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Mekinist 2 mg tablets (30-count units) under a firm fixed-price contract valued at $19,341.02. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy used primarily for...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP2E3Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) under a competitive procurement with no set-aside designation. The contract, valued at $19,341.02, is scheduled for completion by July 11, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. This award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's demonstrated capability to fulfill federal medical procurement requirements through open competition, combined with its established role as a critical pharmaceutical distributor for the Defense Health Agency and other government healthcare systems, positions the company to deliver this and ongoing medical supply needs through the DLA's Pharmaceutical Prime Vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.3k | 6/18/25 |